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A B S T R A C T
Purpose: Epileptic spasms sometimes begin after the ﬁrst year of life, and such seizures are recognized as
late-onset spasms (LOS). The prognosis of LOS is poor, and a treatment strategy has not been established.
This study aimed to assess the short- and long-term effects of adrenocorticotropic hormone (ACTH)
therapy for LOS.
Methods: We investigated the rate of LOS in 22 patients (14 boys and 8 girls) treated with ACTH therapy.
The age at onset of LOS and at the start of ACTH therapy ranged from 12 to 94 months (median,
31.6  22.1 months) and from 12.5 to 116 months (median, 37.5  23.7 months), respectively. We
investigated the response rate of LOS treated with ACTH therapy, and compared the clinical features between
responders (short-term) and nonresponders.
Results: Nine (41%) of the 22 patients showed cessation of epileptic spasms within 3 months. The
epileptic spasms ceased in four of these nine patients for more than 1 year. The age at onset of LOS was
signiﬁcantly associated with short-term seizure cessation (p < 0.05). Patients who achieved short-term
cessation of seizures received ACTH therapy within 6 months from the onset of LOS.
Conclusion: ACTH therapy is a potentially effective treatment when started within 6 months from the
onset of LOS. A younger age at onset of LOS is associated with a favorable outcome.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Epileptic spasms are often the primary seizure manifestation in
patients with West syndrome. These spasms are age-related and
usually begin in the ﬁrst year of life. However, epileptic spasms are
not speciﬁc to West syndrome; in some cases, they occur after the
ﬁrst year of life. Epileptic spasms starting after the ﬁrst year of life
were recently recognized as late-onset spasms (LOS).1–3
Pharmacological treatment of infantile spasms requires adre-
nocorticotropic hormone (ACTH) therapy, which leads to remission
in 50–80% of cases.4 In contrast, the prognosis of LOS is poor,1,2,5
even when drugs that are efﬁcacious for the treatment of infantile
spasms are used.Abbreviations: ACTH, adrenocorticotropic hormone; Cortrosyn-Z, zinc hydroxide
suspension of tetracosactide acetate; EEG, electroencephalography; LOS,
late-onset spasms.
* Corresponding author. Tel.: +81 726 83 1221; fax: +81 726 84 5798.
E-mail address: ZVQ10523@nifty.com (S. Shimakawa).
http://dx.doi.org/10.1016/j.seizure.2014.03.013
1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reWith regard to ACTH therapy for LOS, Eisermann et al. and de
Menezes and Rho reported treatment results in only eight and four
patients of their series, respectively.2,6 Oguni et al. indicated that
ACTH therapy is worth attempting for patients with LOS without
hypsarrhythmia.7 However, interictal electroencephalography
(EEG) of all 10 patients with LOS in the study of Oguni et al.
showed no hypsarrhythmia. Interictal EEG can show hypsar-
rhythmia in LOS.1,3 Therefore, the effect of ACTH therapy on LOS
remains unclear.
This study aimed to assess the effect of ACTH therapy on LOS.
We used ACTH therapy in 22 patients with LOS and retrospectively
analyzed the effect of ACTH therapy among these patients.
2. Methods
We retrospectively analyzed the medical records and interictal
EEG and/or video EEG data of 52 patients with epileptic spasms
occurring after the age of 12 months between 1997 and 2012 at
Osaka Medical College Hospital, Hirakata Municipal Hospital,served.
M. Fukui et al. / Seizure 23 (2014) 521–526522Osaka University Hospital, Osaka Medical Center and the Research
Institute for Maternal and Child Health, and Osaka City General
Hospital. We excluded patients without ACTH treatment. As a
result, 22 patients (14 boys and 8 girls) treated with ACTH therapy
at these hospitals were enrolled in the present study. The onset of
epileptic spasms ranged from the age of 12 to 94 months (median,
31.6  22.1 months). All patients, except for one patient, underwent
ictal video-EEG, which conﬁrmed the presence of epileptic spasms.
The remaining patient was diagnosed by an expert child neurologist
who directly observed the patient’s attack. The presumed etiologies of
epilepsy were a genetic cause (CASK gene mutation, n = 1) and
structural/metabolic causes (n = 15; post-encephalopathy [n = 6],
cortical dysplasia [n = 5], chromosomal disorder [n = 2], giant
arachnoid cyst [n = 1], and mitochondrial disorder [n = 1]). However,
the etiology of epilepsy was unknown in the remaining patients
(n = 6), despite the presence of severe psychomotor development
disorder (Table 1).
ACTH therapy was started at the age of 12.5–116 months
(median, 37.5  23.7 months). Synthetic ACTH (a zinc hydroxide
suspension of tetracosactide acetate [Cortrosyn-Z]) at a dose of
0.0125–0.025 mg/kg was injected every day or every other day for 2
weeks (maximum, 3 weeks). This dose was then tapered during the
subsequent 1 or 2 weeks until discontinuation in a portion of the
patients. The total dose of ACTH in each patient is shown in Table 2.
The mean follow-up period was 49.6  42.2 months (range, 6–166
months) after the ACTH therapy. Other antiepileptic drugs were
administrated before ACTH therapy in all of the patients, except for
one patient. The mean number of other drugs administered was
3.95  3.50. ACTH therapy was performed more than once in three
patients (two times, n = 2; three times, n = 1).
First, to ensure that there were no differences in the clinical
characteristics between patients with LOS undergoing ACTH
therapy and those with LOS not undergoing ACTH therapy, the
clinical features (sex, underlying type of cause, age at onset,
number of patients with other types of seizures, number of
patients with clusters of epileptic spasms, and number of patients
with hypsarrhythmia) were compared between both groups of
patients. Clinical features were analyzed at the ﬁrst treatment of
ACTH therapy in the patients who underwent multiple ACTH
treatments, and subsequent analyses were performed in the same
manner.
To evaluate the clinical characteristics of patients with LOS
undergoing ACTH therapy, we analyzed the following clinical data
for each patient: sex, etiology, age at onset, other seizure types at
onset of epileptic spasms, ACTH treatment lag, interictal and ictal
EEG before and after ACTH therapy (just after ACTH therapy and at
the last follow-up), antiepileptic drugs before ACTH therapy, total
dose of ACTH, effect of ACTH therapy, duration of follow-up period,Table 1
Clinical data of the patients with LOS.
ACTH therapy (+)
n = 22
ACTH therapy ()
n = 30
Gender (male/female) 14/8 18/12
Underlying type of cause Genetic
(n = 1)
Structural/metabolic
(n = 15)
Unknown cause (n = 6)
Genetic (n = 0)
Structural/metabolic
(n = 23)
Unknown cause
(n = 7)
Age at onset of LOS
(months)
31.6  22.1 46.2  33.1
With other seizures (%) 8 (36.4%) 8 (26.7%)
With cluster (%) 22 (100%) 23 (76.7%)
Hypsarrhythmia (%) 7 (31.8%) 8 (26.7%)
LOS, late-onset infantile spasms.and mental outcome. To evaluate the effect of ACTH therapy on
LOS, the timing of assessment was divided into the following two
groups: (i) seizure cessation for 3 months after ACTH therapy
(short-term effect) and (ii) seizure cessation for 12 months after
ACTH therapy (long-term effect). The rate of seizure cessation in
each period was then analyzed. Because two patients who were
followed up for less than 12 months (6 and 8 months) after ACTH
therapy were included in this study, we evaluated the long-term
effect of therapy in the remaining 20 patients.
To identify the clinical features of responders, the patients were
divided into the following two groups: (i) seizure cessation for 3
months (cessation group) and (ii) seizure persistence or relapse
within 3 months (persistent group). The following data were then
compared between the cessation and persistent groups: age at
onset of LOS, underlying type of cause, interictal EEG ﬁndings,
ACTH treatment lag, and total dose of ACTH. Furthermore, the
effect of ACTH therapy was compared between treatments starting
within 6 months from onset and 6 months after onset of LOS. The
underlying type of cause was divided into genetic or structural/
metabolic cause and unknown cause. We then investigated
whether the presence of obvious etiology affected the efﬁcacy of
ACTH therapy.
Statistical analysis was performed using the Mann–Whitney U
test for comparison of age at onset between the patients with and
those without ACTH therapy, as well as for comparison of age at
onset, treatment lag, and dose of ACTH between the cessation and
persistent groups. Differences in the other clinical data between
groups were analyzed using Fisher’s exact test. A p value of <0.05
was considered statistically signiﬁcant.
3. Results
3.1. Characteristics of patients with ACTH therapy
None of the clinical features were signiﬁcantly different
between patients with and those without ACTH therapy (Table 1).
3.2. Effect of ACTH therapy
With regard to the short-term effect of ACTH therapy, nine
(41%) of the 22 patients showed cessation of seizures, whereas the
remaining 13 patients exhibited a poor response. With regard to
the long-term effect of ACTH therapy, four of 20 patients achieved
cessation of epileptic spasms. However, one of the four patients
developed partial seizures 2 months after ACTH therapy. All of the
remaining four patients experienced relapse of their epileptic
spasms. Focal seizures also occurred in addition to epileptic
spasms in two of the four patients, and tonic seizures occurred in
addition to epileptic spasms in the remaining one patient. Epileptic
spasms and other seizures did not cease in these three patients,
despite the administration of antiepileptic drugs.
Before ACTH treatment, interictal EEG showed hypsarrhythmia
in seven patients and diffuse high-voltage slowing (diffuse slow-
wave discharges) associated with diffuse spike-wave discharges,
temporofrontal spikes, or bilateral frontal spikes in one patient
each. In the remaining 12 patients, interictal EEG showed diffuse
spikes in two of 12 patients and focal abnormalities in 10 of 12
patients, with relatively preserved background activity. Among the
patients with focal EEG epileptic abnormalities, these abnormali-
ties were located in the frontal region (n = 5), temporal or
temporofrontal region (n = 3), temporal and occipital regions
(n = 1), and bilateral occipital and frontal regions (n = 1).
These EEG abnormalities disappeared just after ACTH therapy in
ﬁve patients. EEG showed hypsarrhythmia in three of these ﬁve
patients and bilateral temporofrontal spikes and frontal spikes in
one patient each before ACTH therapy. Subsequently, epileptic EEG
Table 2
Clinical data of individual patients with LOS.
No. Gender Etiology Age at
onset of
LOS (mo)
Other
seizure
types
Antiepileptic drugs
before ACTH therapy
Treatment
lag of ACTH
therapy
Interictal EEG
(before ACTH
therapy)
Total dose
of ACTH
(mg/kg)
Short
term
effects
Long-term
effects
(follow-up
>1 year)
Residual EEG
abnormality
(just after
ACTH therapy)
Follow-up
period
(months)
Residual EEG
abnormality
(last follow-up)
Mental
outcomes
1 Male Leigh encephalopathy 18 VPA 1mo Hypsarrhythmia 0.175 + + – 81 – Se
2 Male Down syndrome 16 VPA 4mo Hypsarrhythmia 0.175 + + Bi) F spike 26 – Se
3 Female Encephalopathy 12 CPS LTG, CZP, TPM, VPA 2w L) F spike 0.175 + + – 30 L) F spike Se
4 Male Psychomotor retardation 30 VPA, TPM 3mo L) F, R) mT spike 0.175 + + Bi) F spike 30 Bi) F spike Se
5 Male Psychomotor retardation 12 CPS VPA,LTG,PB, GBP 1mo L) T, R) O spike 0.175 +  Bi) P spike 48 L) pT-O-P, R)
pT-P-O
poly spike
Se
6 Male Hypoxic–ischemic
encephalopathy,
biliary atresia
12 ZNS, VPA, TPM 6mo DSW, Bi) F–T spike 0.175 +  – 40 Diffuse spike Se
7 Female Focal cortical dysplasia 18 VPA, CLB, TPM 6mo R) F spike 0.1125 +  R) F spike 40 R) F spike Se
8 Male Mental retardation,
autism
62 Myoclonic
seizure
VPA 3mo Bi) F spike 0.21 +  L) T spike 58 Diffuse spike Se
9 Male Cortical dysplasia 17 VPA, ZNS 4mo Hypsarrhythmia 0.175 + N.D. R) O spike 6 R) O spike Se
10 Male Chromosome disorder
Dandy–Walker
syndrome
65 VPA 3mo DSW, diffuse spike 0.175   Bi) F spike 16 Bi) F spike Se
11 Female Psychomotor retardation 34 CPS VPA 1mo Hypsarrhythmia 0.175   Diffuse spike 12 R) F spike Se
12 Male Focal cortical dysplasia 12 – 5mo Hypsarrhythmia 0.175   – 118 Diffuse spike Se
13 Male Focal cortical dysplasia 14 VPA, CLB, B6 3mo Hypsarrhythmia 0.175   – 137 Diffuse spike Se
14 Female CASK gene mutation 17 VPA 2mo R) F, Bi) mT spike 0.175   L) O spike 34 Bi) O spike Se
15 Female Hemorrhagic shock
and encephalopathy
20 PB, VPA, PHT, ESM,
ZNS, LTG, TPM
9mo Bi) F spike 0.14   Diffuse spike 50 Diffuse spike Se
16 Male Hemiconvulsion hemiplegia
epilepsy syndrome
29 Myoclonic
seizure CPS
VPA, CLB, CBZ, ZNS,
LTG, PRM, TPM,
B6, ST, GBP, LEV, CLZ
27mo Bi) F–T spike 0.5   Bi) F spike 16 Diffuse spike Se
17 Male Focal cortical dysplasia 30 VPA, CLB 9mo Diffuse spike 0.175   Diffuse spike 44 Diffuse spike Se
18 Female PRES 34 VPA, CLB, TPM 3mo Bi) F spike 0.175   Diffuse spike 23 Diffuse spike Mild
19 Male Arachnoid cyst 36 VPA, CZP, ZNS, B6, NZP 12mo Diffuse spike 0.3   Diffuse spike 166 L) C–P spike Se
20 Female Psychomotor retardation 42 GTC CBZ, VPA, CLB, ESM,
CLZ, ZNS, B6, PHT
10mo DSW, Bi) F spike 0.175   L) F spike 89 Diffuse spike Se
21 Male Hemiconvulsion
hemiplegia epilepsy
syndrome
72 Myoclonic
seizure CPS
CZP, ESM, PHT, ZNS,
CLB, TPM, CBZ, ST,
LEV, AZA, NZP, GBP, LTG
44mo R) F, Bi) O spike 0.34  N.D. R) F spike 8 R) F spike Se
22 Female Mental retardation 94 CPS VPA, ZNS, LTG, CLB,
LEV, ESM
8mo Hypsarrhythmia 0.5   Hypsarrythmia 18 Hypsarrythmia Borderline
AZA, acetazolamide; B6, vitamin B6; Bi), bilateral; C, central; CBZ, carbamazepine; CLB, clobazam; CLZ, clorazepate; CPS, complex partial seizure; CZP, clonazepam; DSW, diffuse slow wave; ESM, ethosuximide; F, frontal; GBP,
gabapentin; L), left; LEV, levetiracetam; LOS, late-onset infantile spasms LTG, lamotrigine; mo, months; mT, midtemporal; NZP, nitrazepam; O, occipital; P, parietal; PB, phenobarbital; PHT, phenytoin; PRES, posterior reversible
encephalopathy; PRM, primidone; pT, post temporal; R), right; Se, severe; ST, sulthiame; T, temporal; TPM, topiramate; VPA, valproic acid; ZNS, zonisamide.
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Fig. 1. Age at onset of LOS. The age at onset of LOS was signiﬁcantly related to
cessation of short-term seizures.
Table 3
Response to therapy according to treatment lag.
Cessation (n = 9) Persistent (n = 13)
Within 6 months from onset 9 7
After 6 months from onset 0 6
Table 4
Response to therapy according to etiology.
Cessation (n = 9) Persistent (n = 13)
Genetic or structural/metabolic
cause
6 10
Unknown cause 3 3
M. Fukui et al. / Seizure 23 (2014) 521–526524abnormalities were apparent during the follow-up period in four of
the ﬁve patients. At the last follow-up, these epileptic EEG
abnormalities disappeared after ACTH therapy in two patients.
Although a residual epileptic EEG abnormality was identiﬁed in the
frontal region just after ACTH therapy in one of these two patients,
this abnormality disappeared 12 months after ACTH therapy. This
patient achieved seizure cessation for more than 12 months.
Epileptic EEG abnormalities before ACTH therapy were character-
ized by hypsarrhythmia in seven patients. Although this hypsar-
rhythmia disappeared in six of these seven patients after ACTH
therapy, the interictal EEG after ACTH therapy was normal in only
two patients; diffuse spikes and focal spikes were identiﬁed in the
remaining two patients each. Hypsarrhythmia presented in only
one patient without change after ACTH therapy at the last follow-
up. Diffuse slow-wave discharges changed into a preserved
background. Therefore, ACTH therapy was also effective for diffuse
slow-wave discharges.
3.3. Clinical characteristics of responders
The age at onset of LOS in the persistent group (38.4  23.6
months) was signiﬁcantly higher than that in the cessation group
(21.9  15.1 months, p < 0.05) (Fig. 1). ACTH treatment lag did not
show a signiﬁcant difference between the persistent group
(10.2  11.8 months) and the cessation group (3.17  1.94 months)
(Fig. 2). However, all of the patients in the cessation group received
ACTH therapy within 6 months after the onset of LOS. Patients who
received ACTH therapy within 6 months from the onset of LOSFig. 2. Treatment lag was not associated with short-term cessation.reached short-term cessation of epileptic spasms at a signiﬁcantly
higher rate than those who received ACTH therapy more than 6
months from the onset of LOS (Table 3, p < 0.02). A total of 66.7% of
LOS patients had genetic or structural/metabolic causes in the
cessation group, and 76.9% of LOS patients had genetic or
structural/metabolic causes in the persistent group. The rate of
patients with an obvious etiology was not signiﬁcantly different
between the persistent group and the cessation group (Table 4). In
the short term, interictal EEG showed hypsarrhythmia in three
patients in the cessation group and four patients in the persistent
group. Additionally, in the short term, interictal EEG showed focal
epileptic EEG abnormalities excluding symmetrical bilateral EEG
foci in four patients in the cessation group and two patients in the
persistent group. The response to ACTH therapy was not
signiﬁcantly different between patients with and without hypsar-
rhythmia and focal features of epileptic EEG abnormalities. The
total amount of ACTH administered was not signiﬁcantly different
between the persistent group (0.25  0.12 mg) and the cessation
group (0.172  0.0237 mg, Fig. 3). However, in eight of nine
patients, LOS ceased at an ACTH dose of less than 0.175 mg/kg
(corresponding to 0.0125 mg/kg/day of ACTH injected every day for
2 weeks), whereas LOS persisted in all of the patients with an ACTH
dose higher than 0.35 mg/kg (corresponding to 0.25 mg/kg/day of
ACTH injected every day for 2 weeks).Fig. 3. Total ACTH dose was not different between the short-term cessation group
and the persistence group. Solid squares indicate patients who achieved short-term
cessation. Open squares indicate patients with persistent LOS.
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The prognosis of LOS is poor,2 and a treatment strategy has not
been established. In previous studies, the effect of ACTH therapy
for LOS was evaluated in a small numbers of patients.2,7 This is the
ﬁrst study on the effect of ACTH therapy on LOS. Nine (41%) of the
22 patients showed cessation of seizures within 3 months. At the
last follow-up, four patients had achieved cessation of epileptic
spasms for more than 1 year.
4.1. Effect of ACTH on epileptic spasms
With regard to infantile spasms, the epileptic spasm and
hypsarrhythmia response rate to synthetic ACTH ranges from 42%
to 76% in patients.8,9 The efﬁcacy of ACTH therapy for epileptic
spasms persisting beyond infancy and epileptic spasms starting to
occur after the ﬁrst year of life is controversial. de Menezes and Rho
found that conventional anticonvulsants (ACTH therapy and
vigabatrin) were often ineffective in completely controlling
unusual epileptic spasms.6 Eisermann et al. described a favorable
effect of ACTH therapy in only one of four patients.2 Oguni et al.
analyzed the effect of ACTH therapy for epileptic spasms without
hypsarrhythmia.7 In seven of 10 patients, epileptic spasms ceased
for 3 months (short-term cessation) after ACTH therapy.7 Although
only six of these 10 patients could be followed up for more than 1
year, one of these six patients achieved freedom from seizures. In
three of these six patients, only epileptic spasms disappeared, but
other seizures developed.7 In our study, nine (41%) of the 22
patients showed cessation of seizures within 3 months. Four (20%)
of 20 patients achieved cessation of epileptic spasms for more than
1 year. During the follow-up period (30–81 months from ACTH
therapy), three patients achieved freedom from seizures. The
number of cases with unknown causes in the study of Oguni et al. is
greater than that in our study, but the rate of patients who
achieved freedom from seizures in our study is similar to that of
Oguni et al. Although the response rate to ACTH was lower in
patients with LOS than those with infantile spasms, 20% of patients
with LOS achieved cessation of epileptic spasms and 15% of
patients with LOS achieved freedom from seizures. Therefore,
ACTH therapy is worth attempting in patients with LOS.
Hydrocortisone is also known to be effective for patients with
LOS.2 Seven of 21 patients achieved cessation of LOS with unknown
causes. Because our study involved cases with an obvious etiology,
it is difﬁcult to compare the efﬁcacy between ACTH and
hydrocortisone. Further studies are required to determine whether
hydrocortisone is more effective than ACTH therapy for LOS.
4.2. Effect of ACTH on interictal EEG
Interictal EEG showed hypsarrhythmia in seven patients.
Eisermann et al. reported that no patients with LOS with an
unknown cause had hypsarrythmia.2 However, in the series of
Auvin et al., one of three patients who developed LOS with
unknown causes had hypsarrythmia.3 In our series, two of seven
patients with unknown causes had hypsarrhythmia. Therefore,
electroclinical features are varied in patients with LOS with
unknown causes.
Hypsarrhythmia was shown to disappear in 80% of patients
with infantile spasms by synthetic ACTH therapy, regardless of the
ACTH dose.10 In our study, hypsarrhythmia disappeared in six of
seven (85.7%) patients with LOS after ACTH therapy. The rate of
disappearance of hypsarrhythmia in LOS is similar to that of
infantile spasms. At the last follow-up period after ACTH
treatment, epileptic EEG abnormalities disappeared in two of 22
patients, and these patients achieved freedom from seizures for
more than 1 year. In a previous study, epileptic EEG abnormalitiesdisappeared at 3 months in half of patients with LOS without
hypsarrhythmia.7 However, the subsequent interictal EEG ﬁndings
were not provided in this previous study. ACTH therapy might be
effective for interictal EEG abnormalities in patients with LOS.
Further investigation of long-term EEG changes after ACTH therapy
is required.
4.3. Clinical features of responders
4.3.1. Age at onset
In the present study, a younger age at onset of LOS was
signiﬁcantly associated with a favorable outcome. For epileptic
spasms developing in patients with West syndrome, the age at
onset does not affect the ﬁnal outcome.11,12 Because patients with
LOS usually have refractory epilepsy and no therapeutic strategy
has been suggested, epileptic spasms developing as LOS are more
refractory to antiepileptic drugs than are epileptic spasms
developing as West syndrome.1–4 The results of the present study
provide the ﬁrst evidence that age at onset of LOS affects outcome.
However, the reason why a younger age at onset of LOS is
associated with a favorable outcome remains unknown. The
persistence of epileptic spasms may be a reﬂection of central
nervous system (CNS) maturity.13 This raises the possibility that
patients who develop LOS at an older age have more severe
developmental disorders and unchanged CNS maturity. However,
in our study, all of the patients had severe developmental
disorders, regardless of whether LOS achieved short- or long-term
cessation. With regard to the presumed etiology of epilepsy, the
rates of patients with encephalopathy, cortical dysplasia, and
chromosomal disorders were not different between the cessation
and persistent groups. Therefore, we could not determine whether
drug-refractory LOS was related to CNS maturity.
4.3.2. Treatment lag
In infantile spasms, a short treatment lag (less than 1 month) is
associated with a good response to ACTH therapy.14 Among
patients with Down syndrome, those with infantile spasms with a
treatment lag of less than 2 months have earlier treatment
responses than those with a treatment lag of more than 2
months.15 However, the difference in the treatment lag for
hydrocortisone therapy is not related to cessation of LOS.2 In
the present study, signiﬁcantly more patients who received ACTH
therapy within 6 months from LOS onset achieved short-term
cessation than those who received ACTH therapy more than 6
months from the onset of LOS. Therefore, ACTH therapy should be
performed within 6 months from the onset of LOS.
4.3.3. Characteristics of interictal EEG
Among patients with infantile spasms, seizure relapse occurs in
patients with focal EEG epileptic abnormalities more frequently
than in those without focal EEG abnormalities.16 However, in our
study, the response to ACTH therapy was not signiﬁcantly different
between patients with and those without focal epileptic EEG
abnormalities. In a previous report, ACTH therapy was effective for
patients with LOS without hypsarrhythmia.7 Therefore, interictal
EEG results before ACTH therapy cannot predict the disappearance
of LOS after ACTH therapy.
4.3.4. Underlying type of cause of LOS
Whether the underlying type of cause of LOS affects the efﬁcacy
of ACTH therapy for infantile spasms is controversial. The
underlying type of cause did not affect the efﬁcacy of ACTH
therapy for infantile spasms in previous reports.17,18 However, the
long-term outcome (1 year) of seizures after ACTH therapy for
infantile spasms in the unknown cause group was more favorable
than that of the genetic or structural/metabolic cause group in the
M. Fukui et al. / Seizure 23 (2014) 521–526526series of Hamano et al.19 In our study, the underlying type of cause
of LOS did not affect the response to ACTH therapy. As described
above, in seven of 10 patients, epileptic spasms ceased in the short-
term after ACTH therapy in the study of Oguni et al.7 However, only
three cases with obvious etiologies were included in their study.
Further investigation of the outcome of LOS with obvious etiology
after ACTH therapy is required.
4.3.5. Dose of ACTH therapy
The total amount of ACTH was not signiﬁcantly different
between the cessation and persistent groups. Eight of nine patients
in the cessation group responded to less than 0.175 mg/kg of ACTH
(corresponding to 0.0125 mg/kg/day injected every day for 2
weeks), and none of the patients treated with more than 0.35 mg/
kg of ACTH (corresponding to 0.25 mg/kg/day injected every day
for 2 weeks) achieved short-term cessation. In patients with
infantile spasms, the daily dose of synthetic ACTH was not shown
to inﬂuence the seizure outcome.20 However, Oguni et al.
suggested that epileptic spasms without hypsarrhythmia might
require a larger dose of ACTH (0.0125–0.05 mg/kg/day injected
every day for 2–3 weeks) than epileptic spasms of West
syndrome.7 Seven of 10 patients with LOS in the study of Oguni
et al. achieved cessation of seizures within 3 months after ACTH
therapy,7 whereas only one of six patients with LOS achieved
cessation of seizures after 1 year. Although a larger dose of ACTH
for the treatment of LOS might be more effective in the short term,
the rate of freedom from seizures for more than 1 year after ACTH
treatment was not different between the study of Oguni et al. and
our study. Further evaluation is required to elucidate the
appropriate dose of ACTH for the treatment of LOS.
5. Conclusions
We assessed the effect of ACTH treatment for LOS among 22
patients. Nine (41%) of these 22 patients showed cessation of
epileptic spasms within 3 months. Four (20%) of 20 patients
achieved cessation of epileptic spasms for more than 1 year. With
regard to the short-term effect of ACTH, a younger age at onset of
LOS was signiﬁcantly related to a favorable outcome. ACTH therapy
is potentially effective if performed within 6 months from the
onset of LOS.
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